Apolipoprotein c-1 induced apoptosis
AssigneeThe Johns Hopkins University
InventorsSubroto Chatterjee, Peter Kwiterowich
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for identifying compounds which inhibit ApoCI and which are useful in the treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction. The invention further provides methods for treating subjects suffering from or at risk of developing atherosclerosis, plaque rupture, apoptosis, or myocardial infarction. The invention further provides methods for diagnosing subjects at suffering from or at risk of developing treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction.
Claims18
A method of determining whether a subject is at risk for developing atherosclerosis-associated plaque rupture or myocardial infarction comprising:
- a) measuring the level of ApoCI protein in a biological sample from the subject;
- and
- b) comparing the level of ApoCI protein in the biological sample from the subject to the level of ApoCI protein from a control,
- wherein an increased level of ApoCI protein as compared to the control indicates that the subject is at risk for developing atherosclerosis-associated plaque rupture or myocardial infarction.
12-16. (canceled)
A method of identifying a compound useful for the treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction comprising:
- a) contacting ApoCI polypeptide with a test compound;
- and
- b) determining whether the test compound binds to ApoCI or inhibits ApoCI activity,
- wherein a test compound that binds to ApoCI or inhibits ApoCI activity is identified as a compound useful for the treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction.
18-28. (canceled)
A method of identifying a compound useful for the treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction comprising:
- a) contacting a cell that expresses ApoCI with a test compound;
- and
- b) determining whether the test compound inhibits ApoCI expression,
- wherein a test compound that inhibits ApoCI expression is identified as a compound useful for the treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction.
30-36. (canceled)
A method of treating a subject suffering from or at risk for developing atherosclerosis, plaque rupture, apoptosis, or myocardial infarction comprising administering to the subject a therapeutically effective amount of an ApoCI inhibitor.
A method of increasing HDL metabolism in a subject, comprising administering to the subject a therapeutically effective amount of an ApoCI inhibitor.
Dependencies are inferred from the claim text.